The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2020 ASCO Highlights
10:04

The University of Kansas Cancer Center 2020 ASCO Highlights

2020 ASCO Update on ES-SCLC: Does the Addition of Anti-CTLA-4 Tremelimumab Improve Outcomes? Is 1L Pembro + EP Combo Improving PFS & OS?

FEATURING Jun Zhang
  • 228 views
  • September 9, 2020
13:10

The University of Kansas Cancer Center 2020 ASCO Highlights

2020 ASCO NSCLC Highlights: Can We Consider Nivo + Ipi a Novel Chemo-Sparing 1L Option for Advanced Disease? How Effective is Tiragolumab Addition to Atezo in 1L PD-L1 Disease?

FEATURING Jun Zhang
  • 142 views
  • September 9, 2020
08:14

The University of Kansas Cancer Center 2020 ASCO Highlights

2020 ASCO Highlights on NSCLC Targeted Therapy: T-DXd for HER2-Mutated, Capmatinib for MET-Amplified, Selpercatinib (LOXO-292) for RET-Altered, Adjuvant Osimertinib for EGFR+ Disease

FEATURING Jun Zhang
  • 127 views
  • September 9, 2020
08:28

The University of Kansas Cancer Center 2020 ASCO Highlights

2020 ASCO Update on mCRC: Does T-DXd Have Potential in HER2+ Disease Refractory to Standard Therapies?

FEATURING Anwaar Saeed
  • 34 views
  • September 9, 2020
12:44

The University of Kansas Cancer Center 2020 ASCO Highlights

2020 ASCO Update on Rectal Cancer: Should We Consider Total Neoadjuvant Therapy With mFOLFIRINOX a New Option for 1L Stage 3/4 Disease?

FEATURING Anwaar Saeed
  • 1,650 views
  • September 9, 2020
  • 1
11:42

The University of Kansas Cancer Center 2020 ASCO Highlights

2020 ASCO Update on MSI-H mCRC: Is Pembrolizumab More Beneficial Than Chemotherapy in 1L Disease?

FEATURING Anwaar Saeed
  • 171 views
  • September 9, 2020
09:40

The University of Kansas Cancer Center 2020 ASCO Highlights

2020 ASCO Update on Gastroesophageal Cancer: Is Cabozantinib + Durvalumab Effective in Advanced Disease?

FEATURING Anwaar Saeed
  • 165 views
  • September 9, 2020
09:55

The University of Kansas Cancer Center 2020 ASCO Highlights

ASCO 2020 Updates on Epithelial Ovarian Cancer: How Effective Is Secondary Cytoreduction in Recurrent Ovarian Cancer? Does Maintenance Olaparib Improve OS?

FEATURING Andrea Jewell, Chelsea Salyer
  • 97 views
  • September 9, 2020
07:24

The University of Kansas Cancer Center 2020 ASCO Highlights

ASCO 2020 Updates on Cervical Cancer and GTD: Sequential Chemo vs. Radiation Alone - What Are the Effects on DFS? Can Treatment of GTT With Avelumab Successfully Replace Polychemotherapy?

FEATURING Andrea Jewell, Chelsea Salyer
  • 148 views
  • September 9, 2020
14:55

The University of Kansas Cancer Center 2020 ASCO Highlights

2020 ASCO Update on Neoadjuvant Therapy in TNBC: Does Sequential AC/T Chemotherapy Yield High pCR? How Effective Is the Addition of Carboplatin?

FEATURING Priyanka Sharma
  • 1,413 views
  • September 9, 2020
  • 3
06:08

The University of Kansas Cancer Center 2020 ASCO Highlights

2020 ASCO Update on Neoadjuvant Therapy in TNBC: How Effective Is the Addition of CPIs for pCR?

FEATURING Priyanka Sharma
  • 331 views
  • September 9, 2020
  • 1
18:35

The University of Kansas Cancer Center 2020 ASCO Highlights

ASCO 2020 Symptoms and Survivorship Highlights: Does Early Palliative Care Improve Outcomes of Patients With High-Risk AML? Is There a Benefit of Early Palliative Care for Patients in Phase 1 Clinical Trials?

FEATURING Elizabeth Wulff-Burchfield
  • 17 views
  • September 7, 2020